Genocea Biosciences Inc. buy Sievi
Summary
This prediction ended on 10.01.22 with a price of €0.94. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -18.26%. This prediction was marked as speculative and is excluded from Sievi's performance statistics.Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Genocea Biosciences Inc. | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
According to Sievi what are the pros and cons of Genocea Biosciences Inc. for the foreseeable future?
Pros
Cons
Comments by Sievi for this prediction
In the thread Genocea Biosciences Inc. diskutieren